News | Antiplatelet and Anticoagulation Therapies | September 09, 2019

Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients

ISAR-REACT 5 trial presented in a Hot Line Session at ESC Congress 2019 together with WCC

Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients

September 9, 2019 — Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary syndrome and a planned invasive strategy. The late-breaking results of the ISAR-REACT 5 trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France together with the World Congress of Cardiology and published in the New England Journal of Medicine.[1] There was no increase in the rate of major bleeding with prasugrel.

In acute coronary syndromes, a dual antiplatelet regimen with a P2Y12 receptor antagonist plus aspirin is the cornerstone of treatment. Prasugrel and ticagrelor provide greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Both drugs are recommended over clopidogrel for 12 months after percutaneous coronary intervention (PCI) in acute coronary syndrome patients with and without ST-segment elevation (STEMI and NSTE-ACS, respectively)[2]. Until now, the relative merits of ticagrelor versus prasugrel for the one-year treatment of acute coronary syndrome patients were unknown.

The ISAR-REACT 5 trial[3] tested the hypothesis that ticagrelor is superior to prasugrel in reducing the primary composite endpoint of death, myocardial infarction or stroke within 12 months in acute coronary syndrome patients intended for an invasive strategy. A total of 4,018 patients were enrolled from 23 centers in Germany and Italy and randomly allocated to prasugrel or ticagrelor.

Patients assigned to ticagrelor received a loading dose as soon as possible after randomization. In other words, the timing of study drug administration was irrespective of clinical presentation and knowledge of coronary anatomy. In the prasugrel group, the timing of study drug initiation depended on clinical presentation. STEMI patients received prasugrel as soon as possible after randomization (i.e. they were pretreated). In patients with NSTE-ACS, administration of the prasugrel loading dose required knowledge of the coronary anatomy.

The primary composite endpoint of death, myocardial infarction or stroke at 12 months occurred in 9.3 percent of patients in the ticagrelor group and 6.9 percent in the prasugrel group (hazard ratio [HR] 1.36; 95 percent confidence interval [CI] 1.09–1.70; p = 0.006).

The incidence of the individual components of the primary endpoint in the ticagrelor and prasugrel groups was 4.5 percent versus 3.7 percent for death, 4.8 percent versus 3 percent for myocardial infarction, and 1.1 percent versus 1 percent for stroke. Definite or probable stent thrombosis occurred in 1.3 percent of patients assigned to ticagrelor and 1 percent assigned to prasugrel, and definite stent thrombosis in 1.1 percent versus 0.6 percent of patients, respectively.

The increase in anti-ischemic efficacy with prasugrel was not accompanied by a raised bleeding risk. Bleeding (BARC class 3 to 5) was observed in 5.4 percent of patients in the ticagrelor group and 4.8 percent of patients in the prasugrel group (HR 1.1; 95 percent CI 0.8–1.5; p = 0.46).

Principal investigator Prof. Stefanie Schuepke of the German Heart Centre Munich said, “In this investigator-initiated, multicentre, randomised clinical trial of invasively treated acute coronary syndrome patients, prasugrel significantly reduced the composite rate of death, myocardial infarction, or stroke compared to ticagrelor with no rise in the rate of major bleeding.”

For more information: www.escardio.org

References

1. Schüpke S., Neumann F-J., Menichelli M., et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, published online Sept. 1, 2019. DOI: 10.1056/NEJMoa1908973

2. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165. doi:10.1093/eurheartj/ehy394.

3. ISAR-REACT: Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment.

Related Content

Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
Overlay Init